Scynexis Inc (SCYX): Total Liabilities
$9.65M
As of 2025-12-31
$8.04M
As of 2026-06-30
-51.5%
3-year compound annual growth
-34.5%
5-year compound annual growth
+2.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.65M | -72.9% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $35.57M | -35.9% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $55.45M | -34.4% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $84.58M | +7.6% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $78.58M | -1.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $79.78M | +80.3% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $44.26M | +101.7% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $21.95M | -10.2% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $24.44M | -2.1% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $24.97M | +241.0% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $7.32M | +17.4% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $6.24M | -81.3% | 2016-03-07, Balance as of period end |
| 2013-12-31 | $33.34M | n/a | 2015-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $7.11M | +1.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| uniQure N.V. (QURE) | 2025-12-31 | $626.01M | +11.1% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
Compare SCYX, CASIF, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗